Navigation path



Novel Approaches to Induce Mucosal Immunity Against TB Using the Combined Adjuvant Strategy of CTA-1 and ISCOMS
Framework programme:
Project number:
EC contribution:
€ 1 100 074
36 months
Starting date:
1 December 2001


The present project combines state-of-the-art research in ISCOMS- and toxin- based adjuvants, with expertise in Mycobacterial infections and vaccine design.  By incorporating the enzymatically active cholera toxin derived CTA1-DD immunoenhancer into ISCOMS, the consortium has obtained an adjuvant with synergistic effects compared to either adjuvant used alone.  This promising adjuvant technology will now be explored in a mucosal tuberculosis (TB) vaccine.  The partners are at the forefront of this expanding field of research and propose to identify the function of this new adjuvant at the cellular and molecular level.  Its immunogenicity will be analysed for mucosal and systemic immune responses and its potential determined for stimulating TB-specific protective immunity following mucosal immunisation.  The study will result in a better understanding of adjuvant functions and how to optimally design mucosal vaccines and TB-specific vaccines in particular.

[+] Read More